23results about "Allergen ingredients" patented technology

The present invention relates to a modified virus-like particle (VLP) of Cucumber Mosaic Virus (CMV) comprising at least one fusion protein, wherein the at least one fusion protein comprises or preferably consists of b) a chimeric CMV polypeptide, wherein the chimeric CMV polypeptide comprises or preferably consists of (iii) a CMV polypeptide, wherein the CMV polypeptide comprises a coat protein of CMV; and (iv) an antigen polypeptide, wherein the antigen polypeptide is inserted into the CMV polypeptide, wherein the insertion of the antigen polypeptide is between amino acid residues corresponding to position 84 and position 85 of SEQ ID NO: 62 of the CMV polypeptide; and (iii) a T helper cell epitope, wherein the T helper cell epitope replaces an N-terminal region of the CMV polypeptide, and wherein preferably the N-terminal region of the CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO: 62.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

Provided are methods of biasing a response of a vaccine recipient's immune system toward protective sensitization. Methods include administering an agent or substance to the site of a subject of a temporally interacting cell-mediated allergic reaction to enhance the resulting level of protective sensitization.

A process for generating a final product comprising or consisting of a purified allergenic extract, comprising: (A) providing a crude allergenic extract, wherein the crude allergenic extract is obtained by isolation from a biological sample; (B) optionally, purifying the crude extract to obtain a purified crude extract, wherein the purifying step comprises: (B1) filtering the crude product to remove the natural microbial load with respect to the biological sample; (C) optionally, purifying the crude extract or the purified crude extract to obtain a purified extract, wherein the purifying step comprises: (C1) filtering the crude extract or the purified crude extract to remove impurities having a molecular weight of less than 5,000 Da. The process is characterized in that it comprises an ultrafiltration step for viruses which is functional for obtaining a final product which comprises or consists of a purified extract of allergens and which is substantially free of viruses and / or mycoplasmas. The present application also relates to a product for medical or diagnostic use, comprising one or more allergen extracts which are natural with respect to the starting biological sample or which are substantially free of viruses and / or mycoplasmas resulting from any external contamination.

The present invention is directed to polypeptides and compositions thereof useful for the prevention or treatment of an allergic disorder and / or inducing a tolerization response to an allergen. More particularly, the invention relates to agents and compositions thereof that useful for the prevention and treatment of allergic disorders and allergic responses to an allergen.

The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an allergen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and food raw materials or edible processed products in which an antigen comprising such a polypeptide is eliminated or reduced, or the polypeptide is cleaved or removed. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

The present invention relates to a modified virus-like particle (VLP) of Cucumber Mosaic Virus (CMV) comprising at least one fusion protein, wherein the at least one fusion protein comprises or preferably consists of b) a chimeric CMV polypeptide, wherein the chimeric CMV polypeptide comprises or preferably consists of (iii) a CMV polypeptide, wherein the CMV polypeptide comprises a coat protein of CMV; and (iv) an antigen polypeptide, wherein the antigen polypeptide is inserted into the CMV polypeptide, wherein the insertion of the antigen polypeptide is between amino acid residues corresponding to position 84 and position 85 of SEQ ID NO: 62 of the CMV polypeptide; and (iii) a T helper cell epitope, wherein the T helper cell epitope replaces an N-terminal region of the CMV polypeptide, and wherein preferably the N-terminal region of the CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO: 62.

The present application provides novel compounds or pharmaceutically acceptable salts thereof having TLR4 activating effects, and useful as immunostimulants or adjuvants in vaccine or allergen immunotherapy. The present application provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof. In the formula (I), X, Y, Z and n are each as defined in the specification.[Formula 1]

The application relates to the technical field of immunization and insect allergy prevention and treatment, and specifically discloses a blood-sucking midge allergen recombinant protein vaccine and a preparation method and application thereof. The blood-sucking midge allergen recombinant protein vaccine comprises a Cul t 1 recombinant protein and an immune adjuvant; the preparation method comprises the following steps: S1, constructing a recombinant expression vector containing a Cul t 1 gene; S2, transfecting the carrier obtained in S1 into mammalian cells for expression; S3, collecting the expression cells in S2 and purifying to obtain the Cul t 1 recombinant protein; and S4, mixing the protein obtained in S3 after purification with the immune adjuvant to prepare the vaccine; and the blood-sucking midge allergen recombinant protein vaccine prepared by the preparation method is applied to the preparation of a medicine for preventing or treating allergic reactions caused by bites of the blood-sucking midge. The recombinant protein vaccine can be used for preventing or treating allergic reactions caused by bites of the blood-sucking midge, and has the advantages of clear components, high safety and good immunization effect.

Compositions and methods are provided for immunizing an individual or population of individuals to generate an immune response that protects against pathogen infection in an antigen-agnostic manner. The protective antigen-agnostic immune response is active for a period of time following immunization, from about 7 days, 10 days, 14 days following immunization, and may be active for at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.

The disclosure provides compositions of a bispecific binding molecule-based degrader that degrades a target protein, such as a protein other than a receptor tyrosine kinase (a non-RTK protein) on a cancer cell, via a lysosomal pathway. The bispecific binding molecule specifically binds to the target protein of interest and to a neuropilin-1 (NRP1). The disclosure also provides methods of using the bispecific binding molecule-based degrader, such as to enhance the therapeutic efficacy of cancer treatment.

This invention relates to an oral immunotherapy (OIT) composition comprising granules that contain an allergenic protein, such as peanut protein, along with a humectant, such as trehalose, and a binder, such as hypromellose. The composition may further comprise a filler, such as mannitol and a lubricant, such as stearic acid. OIT compositions, methods of preparing OIT compositions and methods of treatment of food allergy using OIT compositions are provided.

The present application provides a broussonetia papyrifera pollen allergen and its use. Specifically, the present application provides a broussonetia papyrifera pollen allergen, and a composition containing the broussonetia papyrifera pollen allergen, wherein the broussonetia papyrifera pollen allergen is a sensitizing protein Brop1, and the amino acid sequence of the Brop1 is shown as SEQ ID NO: 4. The Brop1 can be applied to screening, diagnosis, desensitization treatment and the like of allergic allergic diseases such as pollen-induced allergic rhinitis, allergic conjunctivitis and asthma.

The present invention is concerned with single-domain antibodies directed against "absent in melanoma 2" (AIM2). The single-domain antibodies of the present invention can also be combined into a homobivalent or heterobivalent polypeptide comprising two of the provided single-domain antibodies of the present invention. The single-domain antibodies or the bivalent polypeptides can be used in medical applications, preferably for preventing and / or treating an inflammatory disease or condition in a subject.

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and / or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

The present invention relates to food allergen compositions. In particular, the present invention relates to novel compositions and methods for the diagnosis or treatment of food allergies. Specifically, the present invention discloses a novel method of delivering food allergens to an allergic patient by oral administration of a formulation that dissolves and releases the proteins in the stomach. The present invention allows for the treatment of food allergies by delivering food allergens to the intestinal immune system and controlled exposure to the esophagus or oral cavity. The present invention also allows for the assessment of the threshold of clinical reactivity by food provocation without exposure to the esophagus and oral cavity. The present invention can be used in any subject, particularly a human subject, and is applicable to any food allergen.

The present invention relates to a novel nucleic acid structure with improved stability and protein expression levels, and its applications, and more particularly to a nucleic acid structure comprising a coding region for encoding a polypeptide or protein; and a poly(A) tail having a secondary or tertiary structure; and a pharmaceutical composition for vaccines or gene therapy comprising the nucleic acid structure. In the case of the nucleic acid structure platform according to the present invention, improved stability and protein expression rates are observed in cells without interference with CDS, UTR sequences, etc., and therefore it can be widely and usefully used in the fields of gene therapy and vaccines.

The present invention concerns a method of treating peanut allergy in a subject, or a population of subjects, the method comprising administering to said subject or population of subjects a peanut allergen by an oral immunotherapy (OIT) regimen comprising a dose escalation phase in which the peanut allergen is administered in a dose which is increased in increments from an initial dose of the allergen equivalent of 5 mg peanut protein or less to a dose of the allergen equivalent of 200 mg peanut protein or more within 4 to 9 weeks from the administration of the initial dose. The treatment reduces the length of the build-up phase in peanut OIT methods and improves the likelihood or odds of the subject achieving sustained unresponsiveness.

The present invention provides a paper mulberry pollen allergen and a use thereof. Specifically, the present invention provides a paper mulberry pollen allergen and a composition containing the paper mulberry pollen allergen, wherein the paper mulberry pollen allergen is an allergenic protein Brop1, and the amino acid sequence of Brop1 is as shown in SEQ ID NO: 4. Brop1 can be used in the screening, diagnosis, desensitization treatment, etc. of pollen-induced allergic hypersensitivity diseases, such as allergic rhinitis, allergic conjunctivitis, and asthma.

This invention provides a method for enhancing the efficacy, safety, and / or tolerance of grass allergen-specific subcutaneous immunotherapy (SCIT) regimens in subjects with grass allergies. [Solution] A method is provided which includes administering a therapeutic composition containing an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or its antigen-binding fragment, to a subject in need.

The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an allergen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and food raw materials or edible processed products in which an antigen comprising such a polypeptide is eliminated or reduced, or the polypeptide is cleaved or removed. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.